S&P 500 Financials Sector SEC Filings — April 01, 2026

01-04-2026

Lakewood-Amedex Biotherapeutics Inc. (LABT) filed Amendment No. 4 to its Form S-1 registration statement on April 1, 2026, for a direct listing on the Nasdaq Capital Market under the symbol LABT, registering 4,689,177 shares of common stock for resale by existing stockholders, from which the company will receive no proceeds. The company engaged RBW Capital Partners LLC as financial advisor (to receive 272,219 unregistered shares equal to 1.75% of fully diluted shares outstanding) and placement agent (7% fee) for a concurrent private placement of 937,500 shares of Series C Preferred Stock at $10.00 per share, raising $7,500,000 gross proceeds prior to listing. The direct listing process is novel and may result in volatile trading, with Nasdaq approval required and no assurance of listing success.

• ·Series C Preferred Stock stated value $10.00 per share, convertible into common stock at lower of $10.00 or 80% of 5-day average closing price (floor $1.00).
• ·Company classified as emerging growth company and smaller reporting company, electing reduced reporting requirements.
• ·Resale registration statement for Series C underlying common stock and advisory shares to be filed within 10 days of Nasdaq listing.
• ·Listing contingent on Nasdaq approval; if not approved, direct listing will be terminated.

01-04-2026

Weyerhaeuser's 2026 proxy statement highlights strong 2025 performance despite challenging market conditions, including $766 million in cash returned to shareholders, net earnings of $324 million, Adjusted EBITDA of approximately $1.0 billion, and exceeding Climate Solutions Adjusted EBITDA goal with $119 million (42% increase over 2024). The company achieved multi-year targets from 2021 Investor Day, optimized its timberlands portfolio through $469 million in acquisitions and divestitures, increased its quarterly dividend by 5% to $0.21 per share, and launched a growth strategy targeting $1.5 billion incremental Adjusted EBITDA by 2030 from a 2024 baseline. Shareholders are voting on election of 11 directors, advisory approval of NEO compensation, and ratification of KPMG as auditors at the virtual annual meeting on May 15, 2026.

• ·Annual meeting date: May 15, 2026 at 8 a.m. Pacific via virtual webcast at www.virtualshareholdermeeting.com/WY2026.
• ·Record date: March 17, 2026.
• ·Proxy materials distributed on or about April 1, 2026.
• ·Captured $92 million in operational excellence improvements in 2025.
• ·New biocarbon partnership with Aymium to produce up to 1.5 million tons annually by 2030.

01-04-2026

Brag House Holdings, Inc. entered into Amendment No. 3 to its Merger Agreement with Brag House Merger Sub, Inc. and House of Doge Inc., dated March 26, 2026, adding new Section 3.5(i) that imposes modified lock-up restrictions on shares of Purchaser Common Stock received by Company Group A Stockholders (e.g., 80% at Effective Time, reducing to 0% after 270 days), Company Group B Stockholders (80% at Effective Time, to 0% after 270 days), and RSU holders (90-day full lock-up plus 5% daily volume limit thereafter). The amendment also extends the outside date for termination under Section 9.2(a) from April 30, 2026, to May 29, 2026, and requires Purchaser to implement stop transfer orders and legends. No financial terms were altered.

• ·Original Merger Agreement dated October 12, 2025; prior amendments on November 26, 2025 (No. 1) and February 2, 2026 (No. 2).
• ·Lock-up exceptions for domestic relations order, divorce settlement, will, laws of descent and distribution, or applicable law.
• ·Purchaser to instruct Exchange Agent for stop transfer orders and restrictive legends on shares for 90, 180, and 270 days post Effective Time.

01-04-2026

20/20 BioLabs reported FY 2025 revenue of $2.0 million, up 17% YoY from $1.8 million, with gross profit surging 68% to $0.6 million and gross margins expanding 900 bps to 29.6%. Operating expenses fell 35% to $3.9 million, improving the net loss 33% to $3.7 million from $5.6 million, while net cash used in operations decreased to $1.9 million. However, cash balance declined to $1.0 million from $1.8 million, deferred revenue was roughly flat at approximately $0.5 million, and stockholders' equity turned negative at $(19,225).

• ·Nasdaq Capital Market listing under ticker 'AIDX' commenced February 19, 2026.
• ·$5.0 million private placement closed February 19, 2026, with potential for up to $40 million in additional tranches.
• ·Medicare Multi-Cancer Early Detection Screening Act signed into law February 3, 2026, enabling reimbursement pathway by 2028.
• ·Exclusive U.S. license with ROKIT Healthcare for CKD prediction technology integration.
• ·Total assets $4,137,357 as of Dec 31, 2025, up from $3,584,408; total liabilities $4,156,582, up from $2,078,926.

01-04-2026

On March 30, 2026, Nuveen Churchill Private Capital Income Fund entered into an Incentive Fee Waiver Agreement with Churchill PCIF Advisor LLC, waiving 50% of the incentive fee based on income for February 2026, while declaring gross regular distributions of $0.170 per share payable April 28, 2026. As of February 28, 2026, the Fund's aggregate NAV was $1.5 billion, investment portfolio fair value $2.4 billion with a weighted average yield of 8.70%, and it received $120.0 million in Q1 2026 gross subscriptions; however, short-term returns remained modest with Class I shares at 0.21% for 1-month, 1.15% for 3-months, and 0.74% YTD, alongside 3.2% of outstanding shares tendered in the March repurchase offer.

• ·As of February 28, 2026, NAV per share: Class I $24.16, Class S $24.09, Class D $24.16.
• ·Portfolio composition at fair value: 93.08% first-lien debt, 2.75% second-lien debt, 2.02% mezzanine/structured debt, 2.15% equity; 96% floating rate debt.
• ·Average position size 0.30%; top 10 holdings each ~1% of fair value.
• ·Gross regular distributions: Class I $0.170 (net $0.170), Class S $0.170 gross/$0.153 net, Class D $0.170 gross/$0.165 net.

01-04-2026

LFTD Partners recorded significant impairments in 2025, including $22,292,767 on Lifted Goodwill and $800,027 on Oculus Goodwill, both reduced to $0, plus full impairment on its $399,200 Ablis investment to $0 and partial impairment on Bendistillery investment to $99,800; these stem from 'the Act' threatening ~52% of sales from hemp-derived products. While net cash from operating activities improved sharply to $1,321,503 in 2025 from $(960,067) in 2024, the company faces acute regulatory risks including state bans, potential inventory/write-offs by November 12, 2026, and declining stock prices (Q4 2025 high $0.30 vs Q4 2024 $0.79). Additional pressures include low trading volume, no national exchange listing, and potential workforce reductions.

• ·Net cash used in investing activities 2023: $(2,516,955)
• ·Net cash from financing activities 2023: $3,704,945
• ·Stock low prices declined across quarters: Q1 2025 $0.26 (vs Q1 2024 $1.80), Q4 2025 $0.18 (vs Q4 2024 $0.32)
• ·Potential inventory and AR write-offs leading up to November 12, 2026
• ·State regulations: Tennessee HB 1376 effective 2026, Alabama July 1 2025, Minnesota Jan 1 2026, Wisconsin vaping law Sept 1 2025 (nicotine) / July 1 2026 (hemp)

01-04-2026

Zeo Energy Corp.'s 10-K filing details conversion mechanisms for Convertible OpCo Preferred Units into Exchangeable OpCo Units and subsequently Class A Common Stock under maturity date, optional (Sponsor-elected), and transaction event scenarios, all priced relative to $11.00 or market averages. It also discloses key risks including heavy dependence on favorable meteorological conditions for solar energy system sales and installations, reliance on a limited number of suppliers, costly expansion into new sales channels where Zeo may be disadvantaged, and potential stock price declines from substantial public sales of securities by existing holders. No financial performance metrics or period-over-period comparisons are provided in the excerpts.

• ·Early Lock-Up Termination triggers if Class A Common Stock price >= $12/share (adjusted for splits, dividends, etc.) for any 20 trading days within a 30-consecutive trading day period, commencing at least 90 days after Closing.
• ·Maturity Date Conversion uses weighted average daily market price of Class A Common Stock over 5 trading days prior to conversion date.
• ·Supplier risks include potential shortages, delays, price changes, tariffs, or competitor acquisitions leading to sales/installation delays and customer loss.

01-04-2026

For the thirteen weeks ended February 28, 2026, Cal-Maine Foods reported net sales of $666,951 thousand, down 53.0% YoY from $1,417,685 thousand, with net income attributable to the company of $50,459 thousand, down 90.1% from $508,533 thousand, reflecting sharp declines across key metrics. Year-to-date through 39 weeks, net sales fell 25.3% to $2,359,051 thousand from $3,158,227 thousand, and net income dropped 59.8% to $352,558 thousand, though offset by acquisitions like Echo Lake Foods for $275,406 thousand expanding prepared foods capacity. The balance sheet remains solid with total assets at $3,139,261 thousand, up 1.8% from $3,084,619 thousand, driven by higher PP&E and goodwill.

• ·Acquired assets of Clean Egg, LLC for $23.7 million on October 10, 2025, including 677 thousand brown cage-free and free-range layers and pullets.
• ·Subsequent event: Agreement to acquire Creighton Brothers LLC and Crystal Lake LLC announced March 2, 2026.
• ·Goodwill increased to $87,059 thousand from $46,776 thousand due to acquisitions.
• ·Ongoing litigations include Kraft Foods et al v. United Egg Producers and State of Texas v. Cal-Maine Foods.
• ·Dividends payable $16,841 thousand as of Feb 28, 2026, down from $114,163 thousand.

01-04-2026

Haymaker Acquisition Corp. 4 disclosed a Securities Exchange Agreement dated March 26, 2026, under which PubCo (Suncrete, Inc.) will issue 26,000 shares of Series A Convertible Perpetual Preferred Stock with a $1,000 liquidation preference per share and 9% annual dividends to holders of Suncrete’s Senior Preferred Units, automatically prior to the Business Combination closing if Available Cash is below $250M. A new PIPE subscription agreement adds $61.6M commitment from an additional investor, increasing total PIPE investment to $167.1M from the prior $105.5M. Shareholder and Warrantholder meetings were postponed from March 30 to April 2, 2026, extending the redemption request deadline to April 1, 2026.

• ·Series A Preferred Stock convertible at greater of $18.00 per share or 5-day VWAP of PubCo Class A Common Stock.
• ·PubCo may redeem Series A Preferred Stock at liquidation preference plus accrued dividends.
• ·Exchange conditioned on Available Cash < $250M at closing.
• ·Securities issued under Section 4(a)(2)/Regulation D exemption.
• ·Warrantholder Meeting rescheduled to 9:00 a.m. ET April 2, 2026; Shareholder Meeting to 10:00 a.m. ET April 2, 2026.

01-04-2026

ASE Technology Holding Co., Ltd. reported 2025 operating revenues of NT$645,387.7 million (US$20,573.4 million), up 8.4% YoY from NT$595,409.6 million in 2024, with gross profit margin expanding to 17.7% from 16.3%; however, 2024 revenues grew only 2.4% from 2023's NT$581,914.5 million, profit from operations declined 3.1% to NT$40,339.0 million (6.8% margin), and non-operating income turned negative at NT$(117.7) million in 2025. Profit attributable to owners recovered to NT$40,015.7 million (US$1,275.6 million, 6.2% margin) in 2025 after a 8.6% drop in 2024. Total comprehensive income fell 20.8% to NT$37,579.2 million (US$1,197.9 million) in 2025 following a 25.7% rise in 2024, partly due to negative other comprehensive income of NT$(3,617.2) million.

• ·Acquired CHE facility (11,000 sq. ft.) in Cheonan, South Korea and ASE Co., Ltd. - Philippines Branch (148,000 sq. ft.) in Cavite, Philippines in August 2024.
• ·Acquired EugenLight Technologies (98,000 sq. ft.) in Chengdu, P.R.C. in January 2026.
• ·Risks include high cyclicality of semiconductor and electronics industries and potential loss of large customers or disruption of alliances with foundries.

01-04-2026

Loews Corporation filed a DEFA14A (Definitive Additional Proxy Materials) on April 01, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as Definitive Additional Materials. No specific financial data, proposals, or other substantive details are provided in the available content.

01-04-2026

Cadrenal Therapeutics, Inc. entered into a Warrant Inducement Agreement on March 31, 2026, under which a holder will exercise existing warrants for 571,430 shares of common stock at a reduced price of $4.50 per share (from $16.50), providing approximately $2.5 million in gross proceeds for working capital. In exchange, the company issued new Series B-1 and Series B-2 warrants to purchase 571,430 shares each at $4.50 per share, representing significant potential dilution, along with placement agent warrants for 37,143 shares to H.C. Wainwright & Co., LLC and a 7.0% cash fee. A 15-day lock-up on new share issuances follows closing, expected April 1, 2026.

• ·New Warrants exercisable for 5 years (Series B-1) and 18 months (Series B-2) from Resale Registration Statement effectiveness.
• ·Company to file Resale Registration Statement within 30 days of March 31, 2026, and use reasonable efforts for effectiveness within 60 days (or 90 days if SEC review).
• ·Beneficial ownership limit of 4.99% or 9.99% for New Warrant holders.
• ·15-day lock-up on new Common Stock or equivalents post-closing.

01-04-2026

Lamb Weston reported Q3 FY2026 net sales of $1,564.8 million, up 3% YoY driven by 7% volume growth and strong North America performance (+5% sales), but adjusted EBITDA declined 27% to $271.7 million due to unfavorable price/mix, international softness, and a $32.5 million potato write-off. The company raised FY2026 guidance midpoint for net sales to $6.45-6.55 billion and adjusted EBITDA to $1.08-1.14 billion while cutting expected capex to ~$400 million, and declared a $0.38 quarterly dividend; however, International segment sales fell 1% (9% at constant currency) with EBITDA down sharply to $18.5 million.

• ·Closed Munro, Argentina plant and consolidated Latin America production into Mar del Plata facility.
• ·Temporarily curtailed a production line in the Netherlands starting early Q4 FY2026.
• ·Expects to exceed $250 million cost reduction target by FY2028 end.
• ·Q3 FY2026 effective tax rate 35.9% (21.8% excluding comparability items).
• ·Implemented Rule 10b5-1 trading plan for future share repurchases; ~$264M remaining authorized as of Mar 30, 2026.

01-04-2026

Community West Bancshares (CWBC) completed its merger with United Security Bancshares (UBFO) on April 1, 2026, in an all-stock transaction where UBFO shareholders received 0.4520 CWBC shares per UBFO share, valued at approximately $185.5 million based on CWBC's $23.30 closing price on March 31, 2026. The combined company has approximately $5 billion in total assets, retains banking offices across 13 counties and 31 communities in Central California, and features a 14-member board with 12 directors from CWBC and 2 from UBFO. Leadership transitions include James J. Kim as CEO and President, Daniel J. Doyle as Chairman, new Vice Chairman Jagroop “Jay” Gill, and Dennis R. Woods as Chairman Emeritus, alongside retirements of Suzanne M. Chadwick, Tom L. Dobyns, William S. Smittcamp, and upcoming Daniel C. Cunningham.

• ·Shareholder approvals at special meetings on March 30, 2026.
• ·Planned systems conversion in summer 2026.
• ·Exchange ratio: 0.4520 shares of CWBC common stock per share of UBFO common stock.
• ·This is the seventh acquisition for the company, following Community West Bancshares (2024), Folsom Lake Bank (2017), Sierra Vista Bank (2016), Visalia Community Bank (2013), Service 1st Bank (2008), and Bank of Madera County (2005).

01-04-2026

Commercial Vehicle Group (CVGI) announced that Chief Financial Officer Andy Cheung will resign effective April 15, 2026, to become CFO of a mid-cap publicly traded company. Angie O’Leary, current Corporate Controller and Chief Accounting Officer, has been promoted to Interim CFO while retaining her existing roles. The company reaffirmed its full-year 2026 outlook from its Q4 2025 earnings release on March 10, 2026, and stated it does not intend to initiate a search for a permanent CFO replacement at this time.

• ·Angie O’Leary joined CVG as Senior Vice President, Corporate Controller and Chief Accounting Officer in December 2020; previously held roles at Vertiv Holdings Co. from May 2017 to December 2020, including Interim Corporate Controller, and at Deloitte & Touche LLP from January 2004 to May 2017, culminating as Senior Manager – Audit.
• ·Angie O’Leary holds a Bachelor of Science in Business Administration and Master of Accounting from The Ohio State University (2003) and is a Certified Public Accountant since 2005.
• ·Investor contacts: Michelle.Hards@cvgrp.com; Ross Collins or Nathan Skown at Alpha IR Group (15004906036.2).

01-04-2026

Cyclerion Therapeutics, Inc. announced on April 1, 2026, entry into a Merger Agreement with Korsana Biosciences, Inc., involving a two-step merger where Korsana becomes a wholly owned subsidiary before merging into a Cyclerion sub, with pro forma ownership of approximately 1.5% for pre-merger Korsana stockholders and 98.5% for Cyclerion shareholders prior to financing. The transaction requires shareholder approval for share issuances, name change to Korsana Biosciences, Inc., reverse stock split, increased authorized shares, redomiciliation, and Series B Preferred Stock designation, alongside a concurrent financing providing at least $150 million in gross proceeds. While providing minimal dilution and significant new capital, the deal cedes board control rights to Series B holders (electing 4 directors if >=30% outstanding) and includes termination fees and beneficial ownership limits up to 14.99%.

• ·Merger intended as tax-free reorganization under IRC Section 368(a).
• ·Closing conditions include Cyclerion and Korsana stockholder approvals, Nasdaq listing approval, SEC Form S-4 effectiveness, HSR waiting period expiration, and $150M financing in effect.
• ·Cyclerion Board to accelerate vesting of all unvested equity awards pre-closing; underwater options cancelled, in-the-money options cashed out based on Parent Closing Price.
• ·Series B Preferred Stock holders gain veto rights on key actions (e.g., amendments, further issuances, fundamental transactions) and elect 4 Preferred Directors if >=30% outstanding.
• ·Mutual nonsolicitation covenants and termination fees applicable under specified circumstances.

01-04-2026

ADAPTIN BIO, INC. reported a widened net loss of $5,167,569 for the year ended December 31, 2025, up 65% from $3,122,557 in 2024, primarily due to total operating expenses surging 111% to $5,414,943 driven by a 389% increase in general and administrative expenses to $3,640,777, although research and development expenses declined slightly 3% to $1,774,166. Cash and cash equivalents grew significantly to $459,174 from $34,085, fueled by $5,202,981 in net financing activities including private placements, while net cash used in operating activities escalated to $(4,777,892) from $(649,283). Total assets increased to $619,159 from $239,415, and stockholders' deficit improved to $(1,489,396) from $(4,100,116) following recapitalization and debt conversions.

• ·Common stock shares outstanding increased to 8,655,829 as of Dec 31, 2025 from 3,249,999 as of Dec 31, 2024 following recapitalization, private placements, and debt conversions.
• ·Net loss per share improved to $(0.66) from $(0.96) basic and diluted.
• ·Proceeds from common stock and warrants in private placements: $7,161,504 in 2025.
• ·Convertible notes and accrued interest converted into common stock: $1,653,811 non-cash.
• ·Forgiveness of accrued consulting fees by related parties: $345,900.

01-04-2026

TCW ETF Trust plans to convert the TCW MetWest Sustainable Securitized Mutual Fund (MWESX) into the TCW Securitized Income ETF around June 5, 2026, broadening its focus from sustainable securitized bonds to a diversified portfolio across Agency/non-Agency RMBS, CMBS, ABS, and CLOs while retaining the same investment process and track record from September 2021. Existing MWESX shareholders will automatically receive ETF shares of equal NAV if held in a brokerage account, with an information statement/prospectus mailed in early May 2026; non-brokerage holders will receive cash, potentially triggering taxes. The ETF targets a mid-BBB credit profile, 1-3 year duration, and aims to outperform securitized peers through security selection and sector allocation.

• ·Shareholders without brokerage accounts will have investments liquidated to cash, potentially taxable.
• ·ETF secondary benchmark: ICE BofA Low Duration U.S. ABS & CMBS Equal Par Index (CAEQ).
• ·Primary benchmark retained: Bloomberg U.S. Aggregate Index.
• ·Expected reduced Agency MBS exposure and increased ABS/CLO exposure relative to MWESX.
• ·Morningstar category: Securitized Bond – Diversified.

01-04-2026

IceCure Medical Ltd., a commercial-stage medical device company specializing in cryoablation systems like ProSense, filed an F-1 registration statement on April 1, 2026, for the resale of up to 16,000,000 Ordinary Shares by selling shareholders underlying warrants from the March 2026 Offering, which raised $4.0M gross from selling 8,000,000 shares at $0.50 each and issued warrants potentially yielding $8.8M more upon exercise. With 81,180,045 shares outstanding as of March 31, 2026, the filing highlights significant dilution risks, including up to 31.7% increase in outstanding shares if all warrants and options are exercised. Proceeds from warrant exercises, if any, will fund working capital, while the company notes its emerging growth and foreign private issuer status providing reporting exemptions.

• ·Series B Warrants: exercisable immediately, expire in 5 years at $0.55/share.
• ·Series C Warrants: exercisable immediately, expire in 1 year at $0.55/share.
• ·ProSense system FDA authorized for low-risk breast cancer in women aged 70+.
• ·Emerging growth company until revenue exceeds $1.235B, non-affiliate market value over $700M, or $1B debt issued.

01-04-2026

Community Health Systems, Inc. completed the sale of substantially all assets and certain liabilities of Crestwood Medical Center and associated outpatient centers in Huntsville, Alabama, to The Health Care Authority of the City of Huntsville d/b/a Huntsville Hospital Health System on April 1, 2026, for $459 million in cash (subject to post-closing adjustments). The transaction resulted in an estimated pre-tax gain of $185 million ($138 million after tax), boosting pro forma cash by $450 million and improving stockholders' deficit. However, pro forma net operating revenues declined by $327 million, and net loss attributable to stockholders increased to $610 million from $509 million for the year ended December 31, 2025.

• ·Agreement entered into on January 20, 2026.
• ·Facility operations do not qualify as discontinued operations under ASC 205.
• ·Pro forma adjustments eliminate $327M revenues, $123M salaries/benefits, $63M supplies, $88M other operating expenses, $11M lease cost, $13M depreciation/amortization, and reflect $185M gain/(loss) on sale.

01-04-2026

Extra Space Storage Inc. (EXR) filed a DEFA14A Definitive Additional Materials proxy statement with the SEC on April 01, 2026. This is supplemental proxy material pursuant to Section 14(a) of the Securities Exchange Act of 1934, filed by the registrant with no fee required. No financial metrics, performance data, or specific agenda items are detailed in the provided filing content.

01-04-2026

The Morgan Stanley Bitcoin Trust, a Delaware statutory trust formed on December 16, 2025, filed an S-1/A registration statement on April 1, 2026, to enable continuous issuance of shares representing fractional ownership of Bitcoin for public offering and exchange listing. Operational duties are delegated to a Delaware sponsor (formed September 19, 1980), with trustees CSC Delaware Trust Company and AGS Trustees Limited, and key service providers including Bank of New York Mellon (administrator, transfer agent, cash/Bitcoin custodian) and Coinbase Custody Trust Company, LLC (Bitcoin custodian), supported by a low 0.14% annualized Delegated Sponsor Fee covering most expenses. However, Bitcoin custody insurance is shared, excludes value loss, and may not fully cover theft or other risks, with no FDIC insurance.

• ·Trust Agreement amended and restated; Delegation of Trustee Duties and Trustee Services Agreements dated March 25, 2026
• ·Delegated Sponsor handles day-to-day operations including custody control, expense payments, and share issuance
• ·Bitcoin held primarily in multi-layer cold storage; limited hot wallet use for creations/redemptions
• ·Extraordinary expenses (e.g., litigation, taxes) not covered by sponsor fee and paid from Bitcoin holdings
• ·No predetermined cap on sponsor-paid expenses currently

01-04-2026

Postal Realty Trust, Inc.'s DEF 14A proxy statement details the Audit Committee's review and approval of the 2025 audited financial statements with Deloitte & Touche LLP, confirming auditor independence, with no material whistleblower complaints reported. It describes board leadership separating CEO and Chair roles, governance policies including a code of business conduct, whistleblower policy, and stakeholder engagement with over 60 stockholder meetings covering 60% of Class A shares. Beneficial ownership as of March 16, 2026, shows FMR LLC holding 10.3% of Class A common stock (largest 5% owner) and all directors/executives as a group owning 4.7% of Class A shares or 12.5% including OP units, with no pledged shares.

• ·No corporate resources expended for political advocacy or contributions in 2025 except Nareit dues.
• ·No material complaints or submissions received through whistleblower process since implementation.
• ·No shares or units beneficially owned by any executive officer or director have been pledged as of filing date.
• ·Board leadership structure separates CEO (strategic direction and operations) and Chair (guidance, agendas) roles.

01-04-2026

Charlotte’s Web Holdings entered a subscription agreement with BAT for a US$10 million equity investment via up to 14.8 million common shares and will amend its existing US$54 million convertible debenture (originally issued 2022) to lower the conversion price to C$0.94/share and raise the ownership cap from 19.9% to 40.8%, enabling conversion into 95.3 million shares upon closing around May 28, 2026. This represents a total US$75 million equity commitment from BAT, providing critical capital. However, it causes significant shareholder dilution (outstanding shares rising from 159.7 million to 269.7 million) and grants BAT proportional board nomination rights (minimum 2 directors if >=10% ownership), pre-emptive rights, top-up rights, and veto powers over key actions like indebtedness >US$10 million.

• ·Convertible Debenture interest: 5% until US federal CBD regulation in food/supplements, then 1.5%; matures November 14, 2029
• ·BAT standstill provision for 2 years post-Amended IRA (no actions to reach 49%+ ownership)
• ·BAT share transfer restriction for 18 months post-Amended IRA (with exceptions)
• ·BAT demand registration rights: up to 3 times total, once per 12 months
• ·Subscription Agreement dated March 30, 2026; original debenture November 14, 2022

01-04-2026

Axsome Therapeutics, Inc. announced on April 1, 2026, the acquisition of Balipodect, a selective PDE10A inhibitor, for the treatment of schizophrenia and other neuropsychiatric conditions via a press release filed as Exhibit 99.1. The filing was signed by Herriot Tabuteau, M.D., President and Chief Executive Officer. No financial terms or performance metrics were disclosed in the 8-K.

01-04-2026

SharonAI Holdings Inc. issued a press release on March 31, 2026, reviewing its 2025 fiscal year and certain key events subsequent to December 31, 2025. The company also prepared a Presentation Deck dated March 2026 to discuss its business with interested parties. These materials are furnished under Item 7.01 as Regulation FD Disclosure and attached as Exhibits 99.1 and 99.2, respectively, and are not deemed 'filed' under the Exchange Act.

01-04-2026

Innate Pharma SA's revenue from collaboration and licensing agreements plummeted 78% YoY to €2,787 thousand in 2025 from €12,622 thousand in 2024, driving total revenue and other income down 55% to €9,005 thousand, while government financing for research declined 17% to €6,205 thousand. R&D expenses decreased 16% to €43,620 thousand and G&A expenses edged down 2% to €19,394 thousand, but operating loss widened 5% to €54,008 thousand; net loss remained nearly flat at €49,177 thousand, buoyed by net financial income rising 130% to €4,831 thousand.

• ·Proceeds from monalizumab agreement with AstraZeneca: €220 thousand in 2025 (down from €4,404 thousand in 2024)
• ·Sanofi agreement 2022 - ANKET IPH62: €400 thousand in 2025 (similar to €401 thousand in 2024)
• ·R&D sub-total programs in clinical development: €18,231 thousand in 2025 (down from €25,565 thousand in 2024)
• ·IPH4502 R&D expenses: €3,405 thousand in 2025 (down sharply from €9,695 thousand in 2024)
• ·Restructuring costs in R&D: €2,306 thousand in 2025 (none in 2024)
• ·Foreign exchange gains drove financial income higher: €5,883 thousand in 2025 vs €1,658 thousand in 2024

01-04-2026

Coca-Cola Europacific Partners plc (CCEP) announced the appointment of Svetlana Walker as General Counsel and Company Secretary effective April 1, 2026, succeeding Clare Wardle who has stepped down after significant contributions. Svetlana Walker brings over 20 years of international legal and compliance experience, most recently as General Counsel and Chief Compliance Officer at Klöckner Pentaplast Group. CCEP serves nearly 600 million consumers and over 4 million customers across 31 countries.

• ·CCEP listed on Euronext Amsterdam, NASDAQ (NASDAQ 100 constituent), London Stock Exchange, and Spanish Stock Exchanges under symbol CCEP (ISIN GB00BDCPN049).

01-04-2026

Piedmont Natural Gas Company, Inc. (PNG), a subsidiary of Duke Energy CORP, completed the sale of its Piedmont Tennessee business (PNG TN) to Spire, Inc. on March 31, 2026, for expected proceeds of $2.48 billion. Pro forma results for the year ended December 31, 2025, show net income increasing to $887 million from historical $440 million, driven by a $693 million gain on sale; however, operating revenues declined to $1,911 million from $2,237 million and core operating income (excluding gain) fell to approximately $560 million from $696 million due to divestiture of the segment, which contributed $149 million to historical operating income. The pro forma balance sheet as of December 31, 2025, reflects higher cash of $1,334 million but lower total assets of $11,830 million versus historical $12,470 million.

• ·Purchase agreement entered July 27, 2025.
• ·Proceeds subject to closing adjustments; $800M used for debt repayment, reducing notes payable and interest expense by $22M.
• ·Estimated tax impact: $347M offset to cash from deferred/current taxes at 24% statutory rate.
• ·Transaction does not qualify as discontinued operation.

01-04-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on April 1, 2026, under Item 8.01 announcing the issuance of a press release titled 'AITX's RAD Retained Through Property Sale as New Owner Validates Autonomous Security Performance.' The press release, attached as Exhibit 99.1, highlights the retention of AITX's RAD system by a property's new owner post-sale, validating its autonomous security capabilities. No financial metrics or period comparisons were disclosed.

• ·Filing is furnished under Item 8.01 and not deemed 'filed' for liability purposes.
• ·Registrant details: Nevada incorporation, CIK 0001498148, EIN 27-2343603, principal office at 10800 Galaxie Avenue, Ferndale, Michigan 48220.

01-04-2026

McCormick & Company, Incorporated filed a Rule 425 communication under the Securities Act of 1933 concerning Unilever PLC (Commission File No. 001-04546), dated March 31, 2026, and submitted to the SEC on April 1, 2026. This filing pertains to M&A-related disclosures in connection with a potential business combination or tender offer. No specific financial metrics, terms, or outcomes are detailed in the provided content.

• ·Filed pursuant to Rule 425 under the Securities Act of 1933, as amended
• ·Deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended
• ·Document filename: morpheus-495.htm

01-04-2026

Aura Minerals Inc. filed its 20-F Annual Report on April 1, 2026, incorporating S-K 1300 technical report summaries for key assets including the Aranzazu Mine (Mexico), Minosa Mine (Honduras), Apoena Mine (Brazil), Almas Mine (Brazil), Matupá Mine (Brazil), and Borborema Mine (Brazil), all approved by qualified persons. The reports were issued between March 25 and March 30, 2026 (except Apoena in 2025), with effective dates from October 31, 2023, to December 31, 2025. The filing notes that fair value changes in collars for construction projects fluctuate with gold prices but do not reflect expected future profitability.

• ·Aranzazu Mine report issued March 28, 2025, effective December 31, 2024
• ·Minosa Mine (San Andres) report issued March 28, 2025, effective December 31, 2024
• ·Apoena Mine (EPP Complex) report issued March 28, 2025, effective October 31, 2023
• ·Almas Mine report issued March 30, 2026, effective December 31, 2025
• ·Matupá Mine report issued March 25, 2026, effective August 31, 2022 (feasibility) and March 3, 2026 (initial assessment)
• ·Borborema Mine report issued March 30, 2026, effective December 31, 2025

01-04-2026

Golden Entertainment, Inc. held a special shareholder meeting on March 31, 2026, approving the Master Transaction Agreement (MTA) entered on November 6, 2025, with Argento, LLC, VICI Properties Inc., and VICI ROYAL MERGER SUB LLC by a strong majority (20,430,245 votes for vs. 208,131 against). Advisory approval for executive compensation passed (18,321,781 for vs. 2,330,138 against), and the adjournment proposal also approved overwhelmingly (19,538,974 for), though not needed. Approximately 78% of the 26,398,811 outstanding shares were present, meeting quorum requirements.

• ·Record date for special meeting: March 3, 2026
• ·Definitive Proxy Statement filed and mailed: March 6, 2026
• ·No broker non-votes for any proposal

01-04-2026

Consensus Cloud Solutions, Inc. promoted and appointed Adam Varon (61) as Chief Financial Officer and Karel Krulich (50) as Chief Accounting Officer, effective April 1, 2026. Varon's compensation includes an annual base salary of $345,000, eligibility for up to $150,000 annual bonus in 2026, a February 2026 equity grant valued at approximately $400,000 (8,818 performance-based RSUs and 8,818 time-based RSUs), and an additional equity grant of approximately $300,000 (12,637 time-based RSUs). Krulich's package comprises a $327,000 base salary, up to $100,000 bonus, a February 2026 equity grant worth approximately $375,000 (8,267 performance-based RSUs and 8,267 time-based RSUs), and an additional grant of approximately $275,000 (11,584 time-based RSUs).

• ·Equity grants vest over 3 years: 50% of performance-based RSUs based on 2026 financial metrics, remaining 50% based on stock price targets; time-based RSUs in 5 tranches.
• ·Appointments previously announced.
• ·Event and filing date: April 1, 2026.

01-04-2026

On March 30, 2026, the Audit Committee of iRhythm Holdings, Inc. dismissed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm and engaged KPMG LLP for the fiscal year ending December 31, 2026. PwC's audit reports for the fiscal years ended December 31, 2024 and 2025 were unqualified, with no disagreements on accounting principles, financial disclosures, auditing scope, or reportable events through the interim period to March 30, 2026. PwC furnished a letter dated March 31, 2026, agreeing with the company's statements, filed as Exhibit 16.1.

• ·No consultations with KPMG occurred during the two most recent fiscal years or interim period regarding accounting principles, audit opinions, disagreements, or reportable events.
• ·Securities registered: Common Stock, Par Value $0.001 Per Share (IRTC on NASDAQ Global Select Market).

01-04-2026

News Corporation disclosed in an 8-K filing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program for Class A (NWSA) and Class B (NWS) common stock. The program authorizes repurchases of up to $1 billion in aggregate, with daily transaction disclosures to ASX if any occur, and periodic updates in quarterly/annual reports. Exhibits 99.1 and 99.2 contain the specific ASX disclosures on their respective dates, including forward-looking statements about repurchase intentions.

• ·Date of earliest event reported: March 31, 2026
• ·Filing date: April 01, 2026
• ·Registrant details: Delaware incorporation, Commission File Number 001-35769, IRS EIN 46-2950970

01-04-2026

McCormick & Co Inc (MKC-V) filed an 8-K on April 01, 2026, reporting entry into a material definitive agreement under Item 1.01, Regulation FD disclosure under Item 7.01, and financial statements/exhibits under Item 9.01. The filing attaches Exhibit 99.1, a press release dated March 31, 2026. No specific financial metrics, agreements details, or performance data were disclosed in the provided content.

• ·Filing Type: 8-K
• ·Items Reported: 1.01 (Material Definitive Agreement), 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements and Exhibits)
• ·Subcategory: Material Agreement Entry
• ·Exhibit 99.1: Press Release dated March 31, 2026

01-04-2026

WidePoint Corp (WYY) filed an 8-K on April 01, 2026, under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), attaching a transcript of their earnings call as Exhibit 99.1. No specific financial metrics, period-over-period comparisons, or performance details are provided in the filing content. The subcategory mentions Unregistered Securities Sale, but the exhibit focuses on the earnings call transcript.

• ·Filing Type: 8-K
• ·Subcategory: Unregistered Securities Sale

01-04-2026

Innovative Payment Solutions, Inc. amended its Articles of Incorporation, increasing authorized common stock from 1,500,000,000 to 5,000,000,000 shares (par value $0.0001) and authorizing 100,000,000 shares of preferred stock (par value $0.0001). The Board of Directors approved the amendment on January 14, 2026, via resolution to provide flexibility for future financings, strategic transactions, acquisitions, equity incentives, and other purposes. The amendment was filed with the Nevada Secretary of State on January 21, 2026.

• ·Business Number: E0466592013
• ·Filing Number: 20265460428
• ·8-K filed April 01, 2026 (Items 5.03, 9.01)

01-04-2026

Grown Rogue International Inc. issued a press release on March 30, 2026, announcing the rescheduling of its full year 2025 financial results release and related conference call, with the press release furnished as Exhibit 99.1. No specific new dates for the rescheduled release or call were provided in the filing. The disclosure is under Regulation FD and not deemed 'filed' for liability purposes.

• ·Securities: Class A Subordinate Voting Shares (GRUSF on OTCQB, GRIN on CSE)
• ·Emerging growth company status confirmed
• ·Press release dated March 31, 2026 (Exhibit 99.1)

01-04-2026

ASIAFIN HOLDINGS CORP. reported revenue growth of 51.6% YoY to $5,126,250 for FY 2025, with gross profit up 33.7% to $1,903,867 and a shift to operational income of $39,667 from a prior loss of $42,977. However, net loss narrowed but persisted at $120,273 (down 25.7% YoY), driven by SG&A expenses rising 28.0% to $1,874,309 and cost of revenue increasing 64.5% to $3,222,383; total assets grew 14.3% to $4,754,814 while liabilities rose 28.9% to $2,188,648.

• ·Workforce totals 129 employees: Management (4), Analyst Programmer (44), Project Manager and Quality Assurance (55), Sales and Marketing (12), Administration/HR/Finance (14).
• ·Plans to enhance internal controls by adding management staff for SEC reporting and segregating accounting duties.
• ·Weighted average common shares outstanding: 81,895,947 (2025) vs 81,551,838 (2024).
• ·Net loss per share basic and diluted: $(0.00) for both years.

01-04-2026

T-REX Acquisition Corp cured a default on its promissory note secured by the Orofino data center, which had matured on May 15, 2025, with approximately $325,000 in principal and accrued interest due. The company refinanced the debt on March 24, 2026, into two notes: $240,000 due March 24, 2027, and $128,000 due June 20, 2027. A press release titled 'T-REX Acquisition Corp Completes Refinancing of its Orofino, Idaho Data Center' was published on March 31, 2026.

• ·Promissory note secured by Deed of Trust on Orofino, Idaho data center
• ·Note originally matured on May 15, 2025
• ·8-K filed on April 01, 2026 reporting event of March 31, 2026

01-04-2026

TherapeuticsMD, Inc. showed financial improvements in 2025 with license revenue surging 71.6% YoY to $3,022 from $1,761, net loss narrowing to $569 from $2,181, loss from operations improving to $(4,390) from $(6,112), and net cash provided by continuing operating activities more than doubling to $2,454 from $1,170. Cash and cash equivalents increased to $7,483 from $5,059. However, total assets declined 2.9% to $37,656 from $38,822, stockholders' equity dipped 1.8% to $26,876 from $27,370, and the company highlighted risks including full reliance on royalties and ongoing disputes with Mayne Pharma.

• ·Write-off and impairment of patents decreased to $176 in 2025 from $1,268 in 2024.
• ·General and administrative expenses increased to $6,852 in 2025 from $6,096 in 2024.
• ·All revenues derived from royalties related to sales of products by licensees.

01-04-2026

NewHold Investment Corp III, a SPAC, completed its IPO in 2025, raising funds that resulted in $209,220,000 held in the Trust Account from 20,125,000 Class A ordinary shares subject to redemption at $10.40 per share, and reported net income of $4,918,000 for the year ended December 31, 2025, driven by $7,008,000 in interest and other income offsetting $2,090,000 in G&A expenses. However, the company incurred an operating loss of $2,090,000, shareholders' deficit widened to $6,961,000 from $65,000 at year-end 2024 due to accretion and transaction costs, and remains pre-business combination with ongoing risks to complete an acquisition.

• ·Class A ordinary shares basic and diluted net income per share: $0.20 for year ended Dec 31, 2025
• ·Class B ordinary shares basic and diluted net income per share: $0.20 for year ended Dec 31, 2025; $(0.01) for prior period
• ·Weighted average Class A ordinary shares outstanding: 17,354,000 for year ended Dec 31, 2025
• ·Private Placement Units: 780,100 issued at $10.00 per unit
• ·Promissory note – related party: $240,000 outstanding as of Dec 31, 2024 (paid off by 2025)

01-04-2026

ETHZilla Corp generated its first revenue of $6,547 thousand in 2025, up from $0 in 2024, while total assets expanded significantly to $306,297 thousand from $12,764 thousand and stockholders' equity rose to $239,418 thousand. However, general and administrative expenses surged 5,331% to $239,997 thousand, resulting in a loss from operations of $(233,450) thousand and a net loss of $(450,521) thousand, compared to $(14,180) thousand in 2024, driven by $210,081 thousand in net other expenses including large fair value losses on convertible debt and derivatives. Adjusted EBITDA deteriorated to $(218,453) thousand from $(2,299) thousand.

• ·Net loss per common share from continuing operations: $(54.32) in 2025 vs $(28.56) in 2024.
• ·Digital assets: $61,587 thousand as of Dec 31 2025.
• ·Collateralized loan current portion: $31,513 thousand as of Dec 31 2025.
• ·Net loss from discontinued operations: $(6,990) thousand in 2025 vs $(3,554) thousand in 2024.

01-04-2026

D. Boral Acquisition I Corp., a blank-check SPAC, reported total assets of $185,954, including $25,000 in cash and $135,954 in deferred offering costs, as of December 31, 2025, with total liabilities of $227,799 resulting in a shareholders' deficit of $41,845. For the period from inception on April 3, 2025, through December 31, 2025, the company recorded formation and operating expenses of $66,845, leading to a net loss of $66,845 or $0.01 per Class B share. No initial business combination has occurred, and forward-looking risks include challenges in completing a combination and potential conflicts of interest.

• ·Prepaid expenses of $25,000 as of Dec 31, 2025.
• ·Accumulated deficit of $66,845 as of Dec 31, 2025.
• ·Additional paid-in capital of $23,768 as of Dec 31, 2025.
• ·Deferred offering costs included in promissory note – related party: $135,954.
• ·Net cash used in operating activities: $0.
• ·Warrant redemption trigger: Class A ordinary shares at or exceeding $18.00 per share for 10 trading days within a 20-trading day period.

01-04-2026

Osprey Bitcoin Trust's net assets decreased by 24.4% YoY to $136,695,615 as of December 31, 2025 from $180,779,483, reflecting a net operational loss of $13,448,292 driven by $43.0 million unrealized depreciation on Bitcoin investments, compared to a $119.4 million gain in 2024. NAV per share fell 7.6% to $28.12 from $30.43, while total expenses rose 34.4% to $2,132,835. However, the Trust still achieved a realized gain on Bitcoin of $31.7 million, down 39.7% YoY.

• ·No share redemptions in Oct-Nov 2025; 1,080,000 shares redeemed in Dec 2025 at average $28.37 per share.
• ·Paid-in capital remained flat at $76,978,282.
• ·Accumulated net investment loss increased to $7,071,876 from $4,939,041.